! 5. Kramm H, Hansen KE, Gow<strong>in</strong>g E, Bridges A. Successful therapy of rheumatoid arthritis with rituximab: renewed <strong>in</strong>terest <strong>in</strong> the role of B cells <strong>in</strong> the pathogenesis of rheumatoid arthritis. J Cl<strong>in</strong> Rheumatol 2004;10:28-32. 6. Rubbert-Roth A, Tak PP, Zerb<strong>in</strong>i C, et al. Efficacy and safety of various repeat treatment dos<strong>in</strong>g regimens of rituximab <strong>in</strong> patients with active rheumatoid arthritis: results of a Phase III randomized <strong>study</strong> (MIRROR). Rheumatology (Oxford, England) 2010;49:1683-93. 7. Khan A, Scott D. Rituximab after methotrexate failure <strong>in</strong> rheumatoid arthritis: evaluation of the SERENE trial. Expert Op<strong>in</strong> Biol Ther 2011;11:1515-8. 8. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy <strong>in</strong> rheumatoid arthritis. Arthritis and rheumatism 2008;58:2993-9. 9. Leandro MJ, Cambridge G, Ehrenste<strong>in</strong> MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab <strong>in</strong> patients with rheumatoid arthritis. Arthritis and rheumatism 2006;54:613-20. 10. Thurl<strong>in</strong>gs RM, Vos K, Wijbrandts CA, Zw<strong>in</strong>derman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Annals of the rheumatic diseases 2008;67:917-25. 11. Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Op<strong>in</strong> Pharmacol 2003;3:323-8. 12. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab <strong>in</strong> patients with rheumatoid arthritis. Annals of the rheumatic diseases 2011;70:909-20. 13. Boumans MJ, Vos K, Gerlag DM, Tak PP. Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen us<strong>in</strong>g rituximab? Annals of the rheumatic diseases 2011. 14. Humby F, Bombardieri M, Manzo A, et al. Ectopic lymphoid structures support ongo<strong>in</strong>g production of class-switched auto<strong>anti</strong>bodies <strong>in</strong> rheumatoid synovium. PLoS medic<strong>in</strong>e 2009;6:e1. 15. Vos K, Thurl<strong>in</strong>gs RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell <strong>in</strong>filtrate <strong>in</strong> patients with rheumatoid arthritis. Arthritis and rheumatism 2007;56:772-8. 16. L<strong>in</strong>dberg J, af Kl<strong>in</strong>t E, Catr<strong>in</strong>a AI, et al. Effect of <strong>in</strong>fliximab on mRNA expression profiles <strong>in</strong> synovial tissue of rheumatoid arthritis patients. Arthritis research & therapy 2006;8:R179. 17. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The cl<strong>in</strong>ical response to <strong>in</strong>fliximab <strong>in</strong> rheumatoid arthritis is <strong>in</strong> part dependent on pretreatment tumour necrosis factor alpha expression <strong>in</strong> the synovium. Annals of the rheumatic diseases 2008;67:1139-44. 18. Haupl T, Stuhlmuller B, Grutzkau A, Radbruch A, Burmester GR. Does gene expression analysis <strong>in</strong>form us <strong>in</strong> rheumatoid arthritis? Annals of the rheumatic diseases 2010;69 Suppl 1:i37-42. 19. van Baarsen LG, Wijbrandts CA, Gerlag DM, et al. Pharmacogenomics of <strong>in</strong>fliximab treatment us<strong>in</strong>g peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010;11:622-9. 20. Kaufmann M, Pusztai L. Use of standard markers and <strong>in</strong>corporation of molecular markers <strong>in</strong>to breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 2011;117:1575-82. Study: R4RA EudraCT: 2012-002535-28 36 / 34
<strong>Protocol</strong> Version 3 14/01/2013 <strong>Protocol</strong> <strong>Title</strong> : A <strong>Randomised</strong>, <strong>open</strong> <strong>labelled</strong> <strong>study</strong> <strong>in</strong> <strong>anti</strong>-TNFa <strong>in</strong>adequate responders to <strong>in</strong>vestigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab <strong>in</strong> RA (R4-RA) Version: 3 EudraCT reference: 2012-002535-28 Dated: 14 / JANUARY / 2013 CONFIDENTIAL : Further dissem<strong>in</strong>ation of this protocol may only be made with the permission of the Chief Investigator Study: R4RA EudraCT: 2012-002535-28 1 / 34
Change language